Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTONEL WITH CALCIUM (COPACKAGED) vs AREDIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ACTONEL WITH CALCIUM (COPACKAGED) contains risedronate sodium, a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway. This leads to reduced bone turnover and increased bone mineral density. The calcium component is for supplementation to prevent hypocalcemia.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting osteoclast activity.
Treatment and prevention of postmenopausal osteoporosis,Treatment of glucocorticoid-induced osteoporosis,Treatment of Paget's disease of bone
Hypercalcemia of malignancy,Osteolytic bone metastases of breast cancer,Osteolytic lesions of multiple myeloma,Paget's disease of bone (off-label)
Actonel (risedronate) 35 mg orally once weekly, taken with 6-8 oz of plain water at least 30 minutes before breakfast. Calcium supplement (e.g., 1250 mg calcium carbonate) taken with food at a different time of day.
90 mg intravenously over 2 hours every 3-4 weeks for hypercalcemia of malignancy; 90 mg intravenously over 2 hours every 4 weeks for osteolytic bone metastases of breast cancer or multiple myeloma.
Terminal elimination half-life of risedronate is approximately 20 hours for the 5 mg daily dose and 480 hours for the 35 mg weekly dose due to prolonged retention in bone; clinically, the drug accumulates in bone and is slowly released.
Multiphasic; terminal half-life is approximately 300 hours (range 200-400 hours) reflecting slow release from bone. Clinically, this results in prolonged suppression of bone resorption lasting weeks after a single dose.
Risedronate is not metabolized and is eliminated unchanged primarily via renal excretion.
Not metabolized; excreted unchanged in urine.
Risedronate is eliminated primarily via renal excretion, with approximately 50% of an absorbed dose excreted unchanged in urine. Unabsorbed drug is eliminated in feces. Total clearance is about 100 m L/min.
Primarily eliminated unchanged via renal excretion (about 30-40% of administered dose within 24 hours); remainder sequestered in bone and slowly released over months. Biliary/fecal excretion is negligible (<1%).
Risedronate is approximately 24% bound to plasma proteins.
Approximately 54% bound to plasma proteins, primarily albumin.
Volume of distribution for risedronate is approximately 6.3 L/kg, indicating extensive distribution into bone and other tissues.
Steady-state Vd is approximately 0.4-0.6 L/kg, indicating extensive distribution to bone and soft tissues; rapid uptake by bone mineral.
Oral bioavailability of risedronate is low, averaging 0.63% for the 5 mg tablet when taken under fasting conditions; administration with food reduces bioavailability significantly (by up to 50%).
Intravenous: 100% (only route). Oral bioavailability is <1% and clinically irrelevant; no oral formulation available.
Contraindicated if Cr Cl <30 m L/min. For Cr Cl 30-49 m L/min: no dose adjustment needed. For Cr Cl ≥50 m L/min: no adjustment.
For Cr Cl >50 m L/min: no adjustment; Cr Cl 30-50 m L/min: reduce dose to 60 mg; Cr Cl <30 m L/min: not recommended (no data).
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe impairment (Child-Pugh C).
No specific adjustment recommended; use caution in severe hepatic impairment due to limited data.
Not indicated for use in pediatric patients. Safety and efficacy not established.
Safety and efficacy not established for pediatric patients.
No specific dose adjustment required. Caution in patients with decreased renal function; monitor renal status. Increased risk of hypocalcemia if calcium intake inadequate.
No specific dose adjustment required; monitor renal function and fluid status carefully owing to age-related decreased glomerular filtration rate.
None
None
Hypocalcemia must be corrected before therapy,Severe renal impairment (Cr Cl <30 m L/min) is not recommended,Esophageal irritation: instruct patients to swallow with full glass of water and not to lie down for 30 minutes,Osteonecrosis of the jaw (rare, mainly with cancer doses),Atypical femur fractures (rare, with long-term use),Avoid concomitant use with other bisphosphonates
Renal impairment,Osteonecrosis of the jaw,Hypocalcemia,Severe musculoskeletal pain,Atypical femur fractures
Hypocalcemia,Severe renal impairment (Cr Cl <30 m L/min),Inability to sit or stand upright for at least 30 minutes,Hypersensitivity to risedronate or any component,Use in patients with esophageal abnormalities that delay emptying (e.g., stricture, achalasia)
Hypersensitivity to pamidronate or other bisphosphonates,Hypocalcemia
Risedronate absorption is significantly reduced by food, especially dairy products, calcium-rich foods, and beverages other than plain water. Avoid all food, beverages (except plain water), and other medications for at least 30 minutes after the dose. Calcium supplement should be taken with a meal to enhance absorption.
No specific food interactions. Avoid excessive intake of calcium or vitamin D supplements unless prescribed. Maintain adequate hydration.
Risedronate: Pregnancy Category C. Bisphosphonates accumulate in bone and are released slowly; theoretical risk of fetal skeletal abnormalities if exposure occurs before or during pregnancy. No adequate studies in pregnant women; use only if clearly needed. Calcium carbonate: Generally considered safe but excessive doses may cause hypercalcemia-related fetal risks. First trimester: Limited data, avoid if possible. Second/third trimester: Use only if maternal benefit outweighs fetal risk.
Pregnancy Category D. May cause fetal harm when administered to a pregnant woman. In animal reproduction studies, bisphosphonates cause fetal skeletal retardation and decreased fetal weight. There is no adequate and well-controlled study in pregnant women; however, postmarketing reports indicate fetal skeletal abnormalities (e.g., shortened long bones) when bisphosphonates are used during pregnancy. First trimester exposure may be associated with neonatal hypocalcemia and skeletal effects. Second and third trimester exposure may increase risk for fetal skeletal mineralization defects.
Risedronate: Unknown if excreted in human milk; not recommended due to potential for bone growth inhibition. Calcium: Excreted in breast milk at normal maternal intake levels; no adverse effects reported. M/P ratio: Unknown for risedronate; calcium M/P ratio approximately 1.1.
It is not known whether pamidronate is excreted in human milk. The M/P ratio is unknown. Due to potential for skeletal toxicity and hypocalcemia in the nursing infant, advise women not to breastfeed during treatment and for a period after the last dose (at least 1-2 weeks based on half-life).
Risedronate: No specific dose adjustments are recommended in pregnancy due to lack of data; generally avoided. Calcium: No dose adjustment needed; maintain recommended daily intake (1000-1300 mg/day). Pregnancy may increase calcium absorption but no dose change required for supplementation.
No specific dose adjustments are recommended for pregnancy due to lack of pharmacokinetic data. However, physiological changes in pregnancy (increased plasma volume, renal clearance) may reduce drug exposure; nevertheless, because risk outweighs benefit, use is contraindicated. If used despite risk, consider monitoring serum calcium and adjusting dose based on serum calcium response and renal function, but no standard pharmacokinetic-based dosing exists.
Actonel (risedronate) with calcium (copackaged) is used for osteoporosis. Administer risedronate on an empty stomach with plain water, at least 30 minutes before first food, drink, or other medications. Wait at least 30 minutes after risedronate before taking the calcium supplement. Calcium can interfere with risedronate absorption.
Monitor serum calcium, phosphate, and magnesium regularly. Aredia (pamidronate) is contraindicated in severe renal impairment (Cr Cl <30 m L/min). Administer as a slow IV infusion (over at least 2 hours for 90 mg dose; 4 hours for metastatic bone disease) to reduce risk of nephrotoxicity. Hydrate adequately before infusion. Assess for osteonecrosis of the jaw (ONJ) and perform dental exam before therapy. Not recommended in pregnancy and lactation.
Take the risedronate tablet first thing in the morning, at least 30 minutes before eating or drinking anything except plain water.,Swallow the risedronate tablet whole with a full glass of plain water (6-8 oz). Do not crush, chew, or suck the tablet.,Do not lie down for at least 30 minutes after taking risedronate to reduce risk of esophageal irritation.,After taking risedronate, wait at least 30 minutes before taking the calcium supplement provided in the copack.,Take the calcium supplement with food or after a meal to improve absorption and reduce stomach upset.,Report any symptoms of esophageal problems (difficulty or pain on swallowing, heartburn, or retrosternal pain) or jaw pain (possible osteonecrosis of the jaw).
You must have regular blood tests to monitor calcium, phosphate, and magnesium levels.,Report any bone pain, jaw pain, or swelling in your mouth immediately.,Maintain good oral hygiene and undergo a dental check-up before starting treatment.,Drink plenty of fluids before and after each infusion.,This drug is not safe during pregnancy; use effective contraception if applicable.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTONEL WITH CALCIUM (COPACKAGED) vs AREDIA, answered by our medical review team.
ACTONEL WITH CALCIUM (COPACKAGED) is a Bisphosphonate and Calcium Supplement that works by ACTONEL WITH CALCIUM (COPACKAGED) contains risedronate sodium, a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway. This leads to reduced bone turnover and increased bone mineral density. The calcium component is for supplementation to prevent hypocalcemia.. AREDIA is a Bisphosphonate that works by Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting osteoclast activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTONEL WITH CALCIUM (COPACKAGED) and AREDIA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTONEL WITH CALCIUM (COPACKAGED) is: Actonel (risedronate) 35 mg orally once weekly, taken with 6-8 oz of plain water at least 30 minutes before breakfast. Calcium supplement (e.g., 1250 mg calcium carbonate) taken with food at a different time of day.. The standard adult dose of AREDIA is: 90 mg intravenously over 2 hours every 3-4 weeks for hypercalcemia of malignancy; 90 mg intravenously over 2 hours every 4 weeks for osteolytic bone metastases of breast cancer or multiple myeloma.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTONEL WITH CALCIUM (COPACKAGED) and AREDIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTONEL WITH CALCIUM (COPACKAGED) is classified as Category C. Risedronate: Pregnancy Category C. Bisphosphonates accumulate in bone and are released slowly; theoretical risk of fetal skeletal abnormalities if exposure occurs before or during . AREDIA is classified as Category C. Pregnancy Category D. May cause fetal harm when administered to a pregnant woman. In animal reproduction studies, bisphosphonates cause fetal skeletal retardation and decreased fet. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.